Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Rx-360 Takes Hold In India
by Jean-François Tremblay
May 18, 2015
| A version of this story appeared in
Volume 93, Issue 20
The pharmaceutical supply-chain safety group Rx-360 has set up a working group in India about two years after establishing itself in China. The working group is led by representatives from Eli Lilly & Co., Amgen, and the Indian fine chemicals producer Hikal. With headquarters in Washington, D.C., Rx-360 was established six years ago after tainted heparin from China led to the deaths of dozens of U.S. patients. Rx-360 members had earlier complained about difficulty in attracting interest from Indian firms.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X